Page 13 - மெய்நிகர் காங்கிரஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aptose Reports Results for the Second Quarter 2021 Aptose Biosciences Inc. a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results for the three months ended June 30, 2021 and provided a corporate update. The net loss for the quarter ended June 30, 2021 was $13.5 million compared with $15.8 million for the quarter ended June 30, 2020. The net loss for the six months ended … – Conference call and webcast at 5:00 pm EDT today – – Luxeptinib Phase 1a/b studies in AML and B cell malignancies fully enrolled at 750 mg dose – – APTO-253 Phase 1a/b study in AML / MDS treating patients at sixth dose cohort of 210 mg/m2 –

United statesAptose biosciencesSusan pietropaoloExchange commissionLifesci advisorsAptose biosciences incCorporate communications investor relationsVirtual congressLuxeptinib phaseChief executiveClinical studyB cell malignanciesNorth americanInvestor relationsUnited states securitiesSci advisors